NFL Biosciences :
Availability of the Annual Report at 31/12/2022
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces that it has made available to the public and filed with the Autorité des Marchés Financiers (AMF) today, friday 28 avril 2023his report Annual au 31/12/2022.
The Annual Report can be viewed on the company’s website at: https://fr.nflbiosciences.com/investors “Documentation” section.
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company based in the Montpellier region that develops botanical drug candidates for the treatment of addictions. NFL Biosciences aims to bring new therapeutic, natural, safer and more effective solutions to the entire world population, without forgetting countries with low or average income levels. Its most advanced product, called NFL-101, is a standardized, nicotine-free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who wish to quit a natural, safe, simplified and personalized administration alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders.
NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). The company is qualified as an “Innovative Company” eligible for FCPI investment.
More information on www.nflbiosciences.com
Contacts
Bruno Lafont – [email protected] – 04 11 93 76 67
Agence Calyptus – [email protected] – 01 53 65 68 68
2023-04-29 22:03:57
#NFL #Biosciences #Availability #Annual #Report
